Disease · MONDO_0006572

lichen planus

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. lichen planus. Diseases, record MONDO_0006572. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006572

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: lichen planus; Open Targets
Open Targets ID: MONDO_0006572; Open Targets
Other names: Lichen, ruber planus; Open Targets
Disease Ontology: DOID:9201; Disease Ontology
MeSH: D008010; MeSH
NCI Thesaurus: C3189; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 1 of its 30 drugs, from ClinicalTrials.gov; Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SIROLIMUS	CHEMBL413	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TRIAMCINOLONE	CHEMBL1451	Small molecule	Phase 2	ClinicalTrials.gov	3	3	1	Drugs and targets
PIMECROLIMUS	CHEMBL1200686	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
RUXOLITINIB	CHEMBL1789941	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
ACITRETIN	CHEMBL1131	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ALEFACEPT	CHEMBL1201571	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ALITRETINOIN	CHEMBL705	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
APREMILAST	CHEMBL514800	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BARICITINIB	CHEMBL2105759	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets22

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	12	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 3	https://conductscience.org/library/genes/2280	Drugs and targets
IL17A	Interleukin-17A	2	Interleukin 17A inhibitor	Phase 2	https://conductscience.org/library/genes/3605	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	2	Tyrosine-protein kinase JAK1 inhibitor	Phase 2	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Tyrosine-protein kinase JAK2	2	Tyrosine-protein kinase JAK2 inhibitor	Phase 2	https://conductscience.org/library/genes/3717	Drugs and targets
RARA	Retinoid receptor	2	Retinoid receptor agonist	Phase 2	https://conductscience.org/library/genes/5914	Drugs and targets
RARB	Retinoid receptor	2	Retinoid receptor agonist	Phase 2	https://conductscience.org/library/genes/5915	Drugs and targets
RARG	Retinoid receptor	2	Retinoid receptor agonist	Phase 2	https://conductscience.org/library/genes/5916	Drugs and targets
RXRA	Retinoid receptor	2	Retinoid receptor agonist	Phase 2	https://conductscience.org/library/genes/6256	Drugs and targets
RXRB	Retinoid receptor	2	Retinoid receptor agonist	Phase 2	https://conductscience.org/library/genes/6257	Drugs and targets

1 to 10 of 22

See all 22 targets

Trials20

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04300296	PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus	Phase 2	111	2023-08-22	Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris	SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT05593432	A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus	Phase 2	64	2024-10-24	Cutaneous Lichen Planus	RUXOLITINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03858634	A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases	Phase 2	58	2021-12-28	Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis	VIXARELIMAB	Its record names the disease	ClinicalTrials.gov
NCT00285779	Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus	Phase 2	27	2015-03-03	Lichen Planus	ETANERCEPT	Its record names the disease	ClinicalTrials.gov
NCT00297037	Pimecrolimus Cream for Oral Lichen Planus	Phase 2	21	2012-10-17	Oral Lichen Planus	PIMECROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT03697460	Topical Ruxolitinib Lichen Planus	Phase 2	12	2021-08-04	Lichen Planus	RUXOLITINIB	Its record names the disease	ClinicalTrials.gov
NCT05188521	Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus	Phase 2	12	2024-06-11	Cutaneous Lichen Planus	BARICITINIB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT06739551	Systemic Treatment Options for Generalized Lichen Planus	Phase 2	124		Lichen Planus	ACITRETIN, METHOTREXATE	Its record names the disease	ClinicalTrials.gov
NCT01061853	Efficacy of Topical Rapamycin to Treat Chronic Erosive Oral Lichen	Phase 3	76		Oral Lichen Planus	SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01584947	Clinical Trials With a Local Anesthetic Lozenge for the Treatment of Chronic Oral Pain	Phase 2	31		Chronic Pain	BUPIVACAINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 20

See all 20 trials

Comparisons in its trials13

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: deaths from any cause	0 of 60	0 of 32	92	NCT05593432	Trial comparisons
Ruxolitinib Cream 1.5% BID vs Vehicle Cream BID: serious adverse events	0 of 60	0 of 32	92	NCT05593432	Trial comparisons
Double-Blind, Vehicle-Controlled Period: Ruxolitinib Cream 1.5% BID vs Double-Blind, Vehicle-Controlled Period: Vehicle Cream BID: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) During the Double-blind, Vehicle-controlled Period	15 of 31	9 of 32	63	NCT05593432	Trial comparisons
Double-Blind, Vehicle-Controlled Period: Ruxolitinib Cream 1.5% BID vs Double-Blind, Vehicle-Controlled Period: Vehicle Cream BID: Number of Participants With Any ≥Grade 3 TEAE During the Double-blind, Vehicle-controlled Period	0 of 31	0 of 32	63	NCT05593432	Trial comparisons
Open-Label Extension Period: Ruxolitinib Cream 1.5% BID vs Open-Label Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID: Number of Participants With Any ≥Grade 3 TEAE During the Open-label Extension Period	0 of 30	1 of 29	59	NCT05593432	Trial comparisons
Open-Label Extension Period: Ruxolitinib Cream 1.5% BID vs Open-Label Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID: Number of Participants With Any TEAE During the Open-label Extension Period	8 of 30	11 of 29	59	NCT05593432	Trial comparisons
KPL-716 vs Placebo: deaths from any cause	0 of 39	0 of 19	58	NCT03858634	Trial comparisons
KPL-716 vs Placebo: serious adverse events	1 of 39	0 of 19	58	NCT03858634	Trial comparisons
Etanercept vs Placebo Injection: serious adverse events	1 of 24	0 of 14	38	NCT00285779	Trial comparisons
Etanercept vs Placebo Injection: Count of Patients Achieving a Response in Cutaneous or Mucosal Disease at 24 Weeks	4 of 13	5 of 14	27	NCT00285779	Trial comparisons

1 to 10 of 13

See all 13 comparisons in its trials

Papers from its trials11

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21175873	RESULT	1	PubMed
42776548	DERIVED	1	PubMed
39951132	DERIVED	1	PubMed
38260663	DERIVED	1	PubMed
37794275	DERIVED	1	PubMed
37505393	DERIVED	1	PubMed
36197049	DERIVED	1	PubMed
35131254	DERIVED	1	PubMed
26507685	DERIVED	1	PubMed
22910104	DERIVED	1	PubMed

1 to 10 of 11

See all 11 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006572

GET https://conductscience.org/api/diseases/v1/MONDO_0006572/drugs?page=2

API reference For AI assistants